- Home
- ABVC vs CUE Comparison
ABVC vs CUE Comparison
Compare ABVC & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- CUE
- Stock Information
- Founded
- ABVC 2015
- CUE 2014
- Country
- ABVC United States
- CUE United States
- Employees
- ABVC N/A
- CUE N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- CUE Health Care
- Exchange
- ABVC Nasdaq
- CUE Nasdaq
- Market Cap
- ABVC 52.1M
- CUE 61.1M
- IPO Year
- ABVC N/A
- CUE 2018
- Fundamental
- Price
- ABVC $2.84
- CUE $0.70
- Analyst Decision
- ABVC
- CUE Strong Buy
- Analyst Count
- ABVC 0
- CUE 2
- Target Price
- ABVC N/A
- CUE $3.00
- AVG Volume (30 Days)
- ABVC 70.7K
- CUE 215.8K
- Earning Date
- ABVC 11-03-2025
- CUE 11-12-2025
- Dividend Yield
- ABVC N/A
- CUE N/A
- EPS Growth
- ABVC N/A
- CUE N/A
- EPS
- ABVC N/A
- CUE N/A
- Revenue
- ABVC $797,916.00
- CUE $8,286,000.00
- Revenue This Year
- ABVC $735.18
- CUE N/A
- Revenue Next Year
- ABVC N/A
- CUE N/A
- P/E Ratio
- ABVC N/A
- CUE N/A
- Revenue Growth
- ABVC 56.52
- CUE N/A
- 52 Week Low
- ABVC $0.40
- CUE $0.54
- 52 Week High
- ABVC $5.48
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- ABVC 46.98
- CUE 40.92
- Support Level
- ABVC $2.75
- CUE $0.68
- Resistance Level
- ABVC $3.03
- CUE $0.85
- Average True Range (ATR)
- ABVC 0.15
- CUE 0.07
- MACD
- ABVC -0.01
- CUE -0.01
- Stochastic Oscillator
- ABVC 32.79
- CUE 5.83
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.